# A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors

> **NCT01456078** · PHASE2 · COMPLETED · sponsor: **Lund University Hospital** · enrollment: 60 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Liver Metastases

## Interventions

- **DRUG:** 177Lu-DOTA-TATE

## Key facts

- **NCT ID:** NCT01456078
- **Lead sponsor:** Lund University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2018-11
- **Final completion:** 2018-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01456078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01456078, "A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01456078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*